<DOC>
	<DOCNO>NCT00226499</DOCNO>
	<brief_summary>An observer-blind study evaluate GlaxoSmithKline Biologicals ' live attenuate varicella vaccine GlaxoSmithKline Biologicals ' combined measles-mumps-rubella-varicella vaccine prevention varicella disease child . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluate Vaccine Against Chickenpox Combined Vaccine Against 4 Viral Childhood Diseases : Measles , Mumps , Rubella Chickenpox</brief_title>
	<detailed_description>According treatment group allocation , participant receive study vaccine follow antibody titre occurrence varicella disease . This study conduct 2 phase . Phase A include vaccination period observation period efficacy . The efficacy endpoint evaluate least two year vaccination . During period , immunogenicity endpoint evaluate respect immune response 43 day vaccination persistence antibody two year varicella ( subject ) measles , mumps rubella ( subset subject ) . Regarding safety endpoint , SAEs ( include complicate varicella case observe ) assess subject whole Phase A duration , whereas , solicit ( local general ) unsolicited adverse event assess subset subject within 43-day period vaccination . Phase B extension Phase A . It long-term follow-up Year 10 examine long-term efficacy study vaccine clinical varicella disease well long-term persistence antibody varicella ( subject ) measles , mumps rubella ( subset subject ) vaccination .</detailed_description>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : Subjects investigator believe parents/guardians comply requirement protocol whole duration study . Male female subject 12 22 month age time first vaccination . Subjects free obvious health problem , establish medical history physical examination enter study . Written inform consent obtain parents/guardians subject inform risk benefit study , language clearly understand performance study procedure . Subjects whose parents/guardians direct access telephone/mobile phone . Subjects : 1. least one sibling ( negative history varicella disease/vaccination ) home , 2. attend day care center , 3. attend childminders , i.e . someone take care several child , 4. contact least week child without know positive history varicella disease/vaccination , play close physical contact 5 minute . Exclusion criterion : Previous vaccination measles , mumps , rubella and/or varicella . History previous measles , mumps , rubella and/or varicella/ herpes zoster disease . Known exposure measles , mumps , rubella and/or varicella/herpes zoster within 30 day prior start study . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Administration immunoglobulins and/or blood product within three month prior first vaccine dose plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical . Family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine , include systemic allergy egg proteins neomycin . Major congenital defect serious chronic illness . Residence household newborn ( 04 week age ) , pregnant woman varicellasusceptible , person know immunodeficiency person high risk varicella . History neurologic disorder seizure . Use investigational nonregistered product ( drug/vaccine study vaccine ) within 14 day prior vaccination plan use study period . Additional exclusion criterion subject include subset : Administration license vaccine within 14 day prior vaccination plan use approximately 42 day last study vaccine dose ( Day 84 ) exception oral polio vaccine ( OPV ) .</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>22 Months</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>